The introduction of HER2-directed therapies, such as monoclonal antibodies, TKIs, ADCs and, more recently, immunomodulation strategies, has improved the prognosis of patients with advanced breast cancer (ABC). This evidence concerns the gene ERBB2 and breast cancer.